Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Cash from Financing Activities: 2009-2024

Historic Cash from Financing Activities for Assembly Biosciences (ASMB) over the last 16 years, with Dec 2024 value amounting to $29.4 million.

  • Assembly Biosciences' Cash from Financing Activities was N/A to $171.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $191.2 million, marking a year-over-year change of. This contributed to the annual value of $29.4 million for FY2024, which is 113.12% up from last year.
  • Latest data reveals that Assembly Biosciences reported Cash from Financing Activities of $29.4 million as of FY2024, which was up 113.12% from $13.8 million recorded in FY2023.
  • Assembly Biosciences' 5-year Cash from Financing Activities high stood at $53.1 million for FY2021, and its period low was $614,000 during FY2022.
  • Moreover, its 3-year median value for Cash from Financing Activities was $13.8 million (2023), whereas its average is $14.6 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first crashed by 98.84% in 2022, then surged by 2,150.49% in 2023.
  • Yearly analysis of 5 years shows Assembly Biosciences' Cash from Financing Activities stood at $7.6 million in 2020, then skyrocketed by 598.30% to $53.1 million in 2021, then crashed by 98.84% to $614,000 in 2022, then soared by 2,150.49% to $13.8 million in 2023, then spiked by 113.12% to $29.4 million in 2024.